X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (96) 96
Conference Proceeding (6) 6
Patent (2) 2
Publication (2) 2
Book / eBook (1) 1
Book Review (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (56) 56
index medicus (45) 45
endocrinology & metabolism (44) 44
male (40) 40
adult (37) 37
female (35) 35
middle aged (35) 35
insulin (31) 31
diabetes (25) 25
diabetes mellitus, type 2 - drug therapy (24) 24
double-blind method (24) 24
hypoglycemic agents - therapeutic use (21) 21
blood glucose - metabolism (20) 20
hypoglycemic agents - administration & dosage (20) 20
type 2 diabetes (20) 20
cross-over studies (19) 19
glucose (18) 18
glucose clamp technique (18) 18
blood glucose - drug effects (17) 17
pharmacokinetics (17) 17
aged (16) 16
diabetes mellitus, type 2 - blood (16) 16
hypoglycemic agents - pharmacokinetics (16) 16
care and treatment (14) 14
insulin - blood (14) 14
research (14) 14
young adult (13) 13
dosage and administration (12) 12
hypoglycemic agents - adverse effects (11) 11
insulin - administration & dosage (11) 11
adolescent (10) 10
insulin - analogs & derivatives (10) 10
insulin - therapeutic use (10) 10
pharmacodynamics (10) 10
diabetes mellitus (9) 9
diabetes mellitus, type 1 - drug therapy (9) 9
dose-response relationship, drug (9) 9
drug therapy (9) 9
hyperglycemia (9) 9
hypoglycemic agents - pharmacology (9) 9
area under curve (8) 8
dextrose (8) 8
diabetes mellitus, type 1 - blood (8) 8
glucagon (8) 8
injections, subcutaneous (8) 8
treatment outcome (8) 8
basal insulin (7) 7
blood glucose - analysis (7) 7
blood sugar (7) 7
body mass index (7) 7
body weight (7) 7
diabetes mellitus, type 2 - metabolism (7) 7
hypoglycemia (7) 7
insulin - pharmacokinetics (7) 7
insulin resistance (7) 7
insulin therapy (7) 7
insulin, long-acting (7) 7
mellitus (7) 7
nph insulin (7) 7
safety (7) 7
type 1 diabetes (7) 7
analysis (6) 6
c-peptide - blood (6) 6
efficacy (6) 6
glargine (6) 6
glucose metabolism (6) 6
glycemic control (6) 6
original articles (6) 6
administration, inhalation (5) 5
analogs (5) 5
body weight - drug effects (5) 5
drug dosages (5) 5
drug therapy, combination (5) 5
glucosides - therapeutic use (5) 5
insulin - pharmacology (5) 5
insulin glargine (5) 5
insulin lispro (5) 5
obesity - drug therapy (5) 5
patients (5) 5
pharmacology (5) 5
pharmacology & pharmacy (5) 5
type 2 diabetes mellitus (5) 5
abridged index medicus (4) 4
anti-obesity agents - therapeutic use (4) 4
antidiabetic drug (4) 4
blood glucose (4) 4
canagliflozin (4) 4
control (4) 4
diabetes mellitus - drug therapy (4) 4
diabetes mellitus, type 2 - physiopathology (4) 4
diabetes therapy (4) 4
drug administration schedule (4) 4
glucosides - adverse effects (4) 4
glycated hemoglobin a - metabolism (4) 4
health aspects (4) 4
hypoglycemia - chemically induced (4) 4
hypoglycemic agents - blood (4) 4
insulin - metabolism (4) 4
insulin detemir (4) 4
insulin, long-acting - pharmacokinetics (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 400 - 408
Aims MK‐1293 is an insulin glargine that has an amino acid sequence identical to that of Lantus, the originator insulin glargine. Two euglycaemic clamp... 
pharmacokinetics | biosimilar insulin | type 1 diabetes | glycaemic control | insulin analogues | pharmacodynamics | SUBCUTANEOUS INJECTION | METABOLITES | NPH INSULIN | BIOTRANSFORMATION | ULTRALENTE | ENDOCRINOLOGY & METABOLISM | EXPOSURE | United States | Humans | Male | Insulin Glargine - pharmacokinetics | Patient Dropouts | Hypoglycemia - prevention & control | Young Adult | Hypoglycemic Agents - blood | Insulin Glargine - blood | Biotransformation | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Female | Hypoglycemia - chemically induced | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Biosimilar Pharmaceuticals - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Insulin Glargine - adverse effects | Blood Glucose - analysis | Double-Blind Method | Insulin Glargine - therapeutic use | Biosimilar Pharmaceuticals - blood | Biosimilar Pharmaceuticals - adverse effects | Diabetes Mellitus, Type 1 - drug therapy | Cross-Over Studies | Insulin Glargine - analogs & derivatives | European Union | Diabetes Mellitus, Type 1 - blood | Glucose Clamp Technique | Hypoglycemic Agents - adverse effects | Medical research | Metabolites | Type 1 diabetes | Analysis | Medicine, Experimental | Amino acids | Dosage and administration | Research | Insulin | Studies | Amino acid sequence | Diabetes mellitus (insulin dependent) | Diabetes | Diabetes mellitus | Original
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 01/2015, Volume 17, Issue 1, pp. 82 - 90
Aim To determine if the glucagon‐like peptide‐1 (GLP‐1) receptor agonist albiglutide, once weekly, impairs counter‐regulatory responses during hypoglycaemia.... 
type 2 diabetes mellitus | glucose metabolism | GLP‐1 analogue | Glucose metabolism | GLP-1 analogue | Type 2 diabetes mellitus | RISK-FACTORS | GLP-1 | SAFETY | INSULIN-SECRETION | ONCE-WEEKLY ALBIGLUTIDE | 52-WEEK EFFICACY | GLUCAGON-LIKE PEPTIDE-1 | PHARMACOKINETICS | COUNTERREGULATION | ENDOCRINOLOGY & METABOLISM | RECEPTOR AGONIST | Recombinant Proteins - therapeutic use | Glucagon-Like Peptide 1 - administration & dosage | Humans | Middle Aged | Male | Recombinant Proteins - adverse effects | Insulin - blood | Glucagon - blood | Glucagon-Like Peptide 1 - genetics | Hypoglycemia - prevention & control | Hypoglycemic Agents - administration & dosage | Glucagon-Like Peptide 1 - agonists | Adult | Female | Hypoglycemia - chemically induced | Insulin Secretion | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Blood Glucose - analysis | Double-Blind Method | Glucagon-Like Peptide 1 - analogs & derivatives | Pancreas - drug effects | Pancreas - metabolism | Down-Regulation - drug effects | Recombinant Proteins - administration & dosage | Up-Regulation - drug effects | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Glucagon - metabolism | Glucose Clamp Technique | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Somatotropin | Glucagon | Physiological aspects | Glucose | Dextrose | Diabetes therapy | Growth hormones | Diabetes
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2012, Volume 14, Issue 12, pp. 1114 - 1122
Aims To assess the safety, pharmacokinetics and pharmacodynamics of multiple‐ascending doses of the novel glucokinase activator AZD1656 in patients with type 2... 
type 2 diabetes mellitus | glucokinase activator | glucokinase | Glucokinase activator | Glucokinase | Type 2 diabetes mellitus | PATHOGENESIS | INSULIN | METABOLISM | GLUCOSE | ENDOCRINOLOGY & METABOLISM | Single-Blind Method | Gastric Inhibitory Polypeptide - drug effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Incretins - metabolism | Male | Azetidines - pharmacology | Dose-Response Relationship, Drug | Glucokinase - drug effects | Hypoglycemic Agents - administration & dosage | Adult | Female | Glucagon-Like Peptide 1 - drug effects | Hypoglycemic Agents - pharmacokinetics | Azetidines - adverse effects | Azetidines - pharmacokinetics | Treatment Outcome | Glucokinase - metabolism | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Azetidines - administration & dosage | Pyrazines - pharmacokinetics | Peptide Fragments - drug effects | Pyrazines - adverse effects | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Pyrazines - pharmacology | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Care and treatment | Safety and security measures | Metabolites | Isoenzymes | Glucose | Dextrose | Plasma | Diabetes | Rodents
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 11/2014, Volume 16, Issue 11, p. 1070
We assessed safety and efficacy of two selective 11[beta]-HSD1 inhibitors (RO5093151/RO-151 and RO5027383/RO-838) in this randomized, controlled study in... 
Type 2 diabetes | Glucose metabolism | Care and treatment | Glucagon | Body weight | Lipids | Hypoglycemic agents | Glucose | Dextrose | Cortisone | Medical research | Diabetes
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2014, Volume 36, Issue 4, pp. 507 - 515
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 01/2018, Volume 20, Issue 1, pp. 94 - 102
Aim To test the hypothesis that an improving body composition in insulin‐resistant individuals could enhance insulin sensitivity. Methods A total of 16 people... 
body composition | bimagrumab | activin receptor II | HbA1c | insulin resistance | obesity | RECEPTOR | GLUCOSE-TRANSPORT | FATTY-ACIDS | MUSCLE MASS | BROWN ADIPOSE-TISSUE | EXERCISE | LIRAGLUTIDE | OVERWEIGHT | ENDOCRINOLOGY & METABOLISM | WEIGHT | Glucose Intolerance - metabolism | Glycated Hemoglobin A - analysis | Follow-Up Studies | Obesity - drug therapy | Humans | Antibodies, Monoclonal - adverse effects | Anti-Obesity Agents - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Anti-Obesity Agents - therapeutic use | Glucose Intolerance - blood | Antibodies, Blocking - administration & dosage | Glucose Intolerance - drug therapy | Anti-Obesity Agents - pharmacokinetics | Hypoglycemic Agents - administration & dosage | Female | Obesity - diagnostic imaging | Body Mass Index | Hypoglycemic Agents - therapeutic use | Glucose Tolerance Test | Hypoglycemic Agents - pharmacokinetics | Adiposity - drug effects | Anti-Obesity Agents - administration & dosage | Double-Blind Method | Obesity - complications | Insulin Resistance | Antibodies, Monoclonal - pharmacokinetics | Absorptiometry, Photon | Glucose Intolerance - complications | Obesity - metabolism | Positron Emission Tomography Computed Tomography | Pilot Projects | Antibodies, Blocking - adverse effects | Antibodies, Monoclonal - administration & dosage | Adipose Tissue, Brown - diagnostic imaging | Antibodies, Blocking - therapeutic use | Adipose Tissue, Brown - drug effects | Adipose Tissue, Brown - metabolism | Glucose Clamp Technique | Infusions, Intravenous | Thermogenesis - drug effects | Hypoglycemic Agents - adverse effects | Exercise | Blood sugar monitoring | Body weight | Physiological aspects | Glycosylated hemoglobin | Insulin resistance | Glucose tolerance tests | Insulin | Glucose tolerance | Dual energy X-ray absorptiometry | Body mass index | Intravenous administration | Body fat | Hemoglobin | Glucose | Positron emission tomography | Body composition
Journal Article
Diabetes care, ISSN 0149-5992, 11/2018, Volume 41, Issue 11, pp. 2346 - 2352
Journal Article